Edition:
United States

Supernus Pharmaceuticals Inc (SUPN.OQ)

SUPN.OQ on NASDAQ Stock Exchange Global Market

33.70USD
19 May 2017
Change (% chg)

-- (--)
Prev Close
$33.70
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
176,626
52-wk High
$34.20
52-wk Low
$17.12

SUPN.OQ

Chart for SUPN.OQ

About

Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy. In... (more)

Overall

Beta: 1.77
Market Cap(Mil.): $1,694.52
Shares Outstanding(Mil.): 50.28
Dividend: --
Yield (%): --

Financials

  SUPN.OQ Industry Sector
P/E (TTM): 18.11 14.32 17.37
EPS (TTM): 1.86 -- --
ROI: 51.00 -7.73 -5.89
ROE: 63.79 -7.36 -5.30

BRIEF-Supernus announces Q1 earnings per share $0.19

* Q1 earnings per share view $0.23 -- Thomson Reuters I/B/E/S

May 09 2017

BRIEF-Supernus receives final FDA approval for trokendi XR

* Supernus receives final FDA approval for trokendi XR for migraine prophylaxis in adults and adolescents

Apr 05 2017

BRIEF-Supernus announces settlement with Actavis on Trokendi XR patent litigation

* Supernus announces settlement with Actavis on Trokendi XR patent litigation

Mar 07 2017

BRIEF-Cadila Healthcare says Zydus announces settlement with Supernus on Trokendi XR extended-release capsules

* Says Zydus announces settlement with Supernus on Trokendi XR® (Topiramate) extended-release capsules

Mar 07 2017

BRIEF-Supernus announces settlement with Zydus on Trokendi XR patent litigation

* Supernus announces settlement with Zydus on Trokendi XR patent litigation

Mar 06 2017

BRIEF-Supernus Pharmaceuticals files for non-timely 10-K

* Supernus Pharmaceuticals Inc - files for non-timely 10-K Source text: (http://bit.ly/2ldW969) Further company coverage:

Mar 01 2017

BRIEF-Supernus Q4 earnings per share $0.26

* Supernus announces record fourth quarter and full year 2016 financial results

Feb 28 2017

BRIEF-Supernus announces issuance of eighth U.S. patent protecting Trokendi XR

* Supernus announces issuance of eighth U.S. Patent protecting Trokendi XR

Feb 08 2017

BRIEF-Supernus wins seventh patent for epilepsy drug Trokendi

* Supernus announces issuance of seventh u.s. Patent protecting Trokendi XR Source text for Eikon: Further company coverage:

Jan 30 2017

More From Around the Web

Competitors

  Price Chg
Abbott Laboratories (ABT.N) $43.16 +0.18
AstraZeneca plc (AZN.L) 5,119.00 0.00
Eli Lilly and Co (LLY.N) $77.80 -0.50
Shire PLC (SHP.L) 4,861.50 +9.50
Shire PLC (3159084.L) -- --
Smiths Group plc (SMIN.L) 1,572.00 -12.00

Earnings vs. Estimates